e-therapeutics (ETX) Share Price, News & Analysis

Company Overview

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.52 million shs
• Average Volume: 758,869 shs
• Market Capitalization: £52.59 million
• P/E Ratio: N/A
• Dividend Yield: 3.35%
• Price Target: N/A
• Consensus Rating: N/A

ETX Stock Analysis - Frequently Asked Questions

How were e-therapeutics' earnings last quarter?

e-therapeutics plc (LON:ETX) released its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.03.

How do I buy shares of e-therapeutics?

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of e-therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

• Last Earnings: 3/17/2020
• Today: 9/15/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:ETX
• CIK: N/A
• Web: www.etherapeutics.co.uk
• Phone: +44-1993-880000
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£10.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.75%
• Return on Assets: -29.10%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 22.20
• Quick Ratio: 20.13

Sales & Book Value

• Annual Sales: £295 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.07
• Book Value: GBX 5 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 584,330,000
• Free Float: N/A
• Market Cap: £52.59 million
• Optionable: Not Optionable
• Beta: 0.46